Financials in USD. Standardized financial statements.
A compact view of how Lee's Pharmaceutical Holdings Limited turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.44B | $1.40B | $1.05B | $1.23B | $1.27B | $1.22B | $1.22B | $1.14B | $1.01B | $929.82M |
| Revenue Growth? | +2.5% | +32.9% | -14.6% | -2.6% | +4.1% | -0.2% | +7.1% | +12.8% | +8.5% | 0.0% |
| Cost of Revenue? | $706.26M | $646.61M | $501.72M | $462.39M | $459.87M | $435.65M | $420.66M | $391.25M | $326.12M | $261.59M |
| Gross Profit? | $729.39M | $753.36M | $551.31M | $770.75M | $806.28M | $781.07M | $798.26M | $746.37M | $682.40M | $668.24M |
| Gross Margin? | +50.8% | +53.8% | +52.4% | +62.5% | +63.7% | +64.2% | +65.5% | +65.6% | +67.7% | +71.9% |
| Operating Expenses? | $667.92M | $640.21M | $507.76M | $694.49M | $889.38M | $691.18M | $611.30M | $549.66M | $434.30M | $350.86M |
| Operating Income? | $61.47M | $113.14M | $43.55M | $123.02M | -$694,000 | $151.92M | $244.60M | $466.94M | $276.83M | $298.43M |
| EBITDA? | $217.08M | $259.67M | $191.56M | $229.06M | $2.13B | $266.93M | $235.55M | $516.17M | $319.99M | $332.13M |
| Income Before Tax | $72.87M | $98.11M | $30.79M | $67.86M | $1.97B | $134.04M | $122.89M | $446.38M | $257.63M | $282.60M |
| Income Tax Expense | $22.26M | $29.50M | $10.84M | $22.03M | $9.48M | $55.50M | $59.54M | $56.62M | $54.69M | $50.20M |
| Net Income? | $91.92M | $93.10M | $16.70M | $51.28M | $1.99B | $78.53M | $63.34M | $418.27M | $232.56M | $252.00M |
| EPS? | $0.16 | $0.16 | $0.03 | $0.09 | $3.38 | $0.13 | $0.11 | $0.71 | $0.39 | $0.43 |
| Diluted EPS? | $0.16 | $0.16 | $0.03 | $0.09 | $3.37 | $0.13 | $0.11 | $0.70 | $0.39 | $0.43 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality